The role of protease inhibitor therapy in children with HIV infection

Pediatric Drugs

Volumn 4, Issue 9, 2002, Pages 581-607

  Gavin, Patrick J ^a   Yogev, Ram ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PERINATAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION; VIRUS RESISTANCE;

CHILD; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS;

EID: 0036367321     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204090-00004     Document Type: Review

References (167)

1. HIV-1 protease inhibitors: A review for clinicians
2. HIV/AIDS in infants, children and adolescents
3. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1
4. Characteristics of human immunodeficiency virus-infected children at the time of death: An experience in the 1990s
5. The aging cohort of perinatal HIV-infected children in New York City
6. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors
7. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type-1
8. Decreased needs for hospital care and antibiotics in children with advanced HIV-1 disease after protease inhibitor-containing therapy
9. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1 infected children
10. Expenditure for the care of HIV-infected patients in the era of highly active antiretroviral therapy
11. The cost effectiveness of combination antiretroviral therapy for HIV disease
12. The HIV-protease as a therapeutic target for AIDS
13. A structural model for the retroviral proteases
14. Effect of two novel inhibitors of the human immunodeficiency virus protease on the maturation of the gag and gag-pol polyproteins
15. Complete nucleotide sequence of the AIDS virus, HTLV-III
16. HTLV III gag protein is processed in yeast cells by the virus pol-protein
17. Human immunodeficiency virus type-1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells
18. HIV-protease inhibitors
19. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
20. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector
21. Rational design of peptide-based proteinase inhibitors
22. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
23. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
24. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
25. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection
26. Nelfinavir pharmacokinetics in HIV-infected children: A comparison of twice daily and three times daily dosing
27. Protease inhibitor therapy in children with perinatally acquired HIV infection
28. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate
29. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children
30. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
31. Can pennatal HIV infection be eliminated in the United States
32. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children
33. Children with HIV intection: Special cases
34. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants
35. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus
36. Viral load and disease progression in infants infected with human immunodeficiency virus type 1
37. Association of human immunodeficiency virus load early in life with disease progression among HIV-infected infants
38. The relationship between serum human immunodeficiency virus type-1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children
39. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
40. Viral counts count in HIV infection
41. Natural history of HIV-1 cell-free viremia
42. Deficient human immunodeficiency type 1-specific cytotoxic T cell responses in vertically infected children
43. Evolution and transmission of stable CTL mutations in HIV infection
44. Combination treatment with zidovudine, didanosine and nevirapine in infants with human immunodeficiency virus type-1
45. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
46. Lymphocyte subsets in healthy children during the first 5 years of life
47. HIV viral load
48. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddl) in children infected with the human immunodeficiency virus
49. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus
50. Anti-retroviral therapy for HIV-infected children-toward maximal effectiveness
51. Time to hit HIV, early and hard
52. Choosing the best initial therapy for HIV-infection
53. Attaining higher goals in HIV treatment: The central importance of adherence
54. Patient compliance and drug failure in protease inhibitor monotherapy
55. Viral load and CD4+ T-cell changes in patients failing potent protease inhibitor therapy
56. The era of adherence to HIV therapy
57. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
58. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
59. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
60. CD4-cell count in HIV-1-infected individuals remaining viremic with highly active antiretroviral therapy (HAART)
61. Drug compliance in pediatrics
62. A phase I/II study of the protease inhibitor indinavir in children with HIV infection
63. Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus
64. Nelfinavir pharmacokinetics in stable HIV-infected children; the effect of weight and a comparison of BID and TID dosing
65. Preliminary evaluation of nelfinavir pharmacodynamics in stable antiretroviral experienced HIV-infected children following initiation of HAART (PACTG 377)
66. Evaluation of toxicity, tolerability and antiviral efficacy of early d4T+ddI+ nelfinavir therapy in HIV-infected infants: 24-Week preliminary results from the PENTA 7 study
67. Ritonavir (ritonavir) pharmacokinetics and dose requirements in HIV infected children less than two years of age
68. HIV protease inhibitors: Pharmacokinetic and metabolic distinctions
69. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection
70. Protease inhibitors: Resistance, cross resistance, fitness and the choice of initial and salvage therapies
71. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
72. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
73. Viral dynamics in human immunodeficiency virus type 1 infection
74. Fidelity of HIV reverse transcriptase
75. The accuracy of reverse transcriptase from HIV-1
76. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
77. Antiretroviral treatment in 1998
78. Resistance to human immunodeficiency type-1 protease inhibitors
79. Antiretroviral drug resistance testing in adult HIV-1 infection
80. Genotypic mutations in the protease and reverse transcriptase genes associated with antiretroviral resistance to combination therapy with ritonavir/AZT/3TC: A virologic sub-study of PACTG 345
81. HIV drug resistance analysis during clinical studies with the protease inhibitor amprenavir
82. Cross-resistance to amprenavir in Pl-treated patients
83. Treatment of HIV-infected children with Kaletra (lopinavir/ritonavir) oral solution: 60 Week follow up
84. Factors affecting long-term virologic suppression in phase II studies of lopinavir/ritonavir in ARV-naive or PI-experienced patients
85. In vivo resistance to a human immunodeficiency virus type-1 proteinase inhibitor: Mutations, kinetics and frequencies
86. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice
87. Drug resistance during indinavir therapy is caused by mutations in the protease gene and its gag substrate cleavage sites
88. Adverse effects of antiretroviral therapy
89. Nelfinavir: An update on its use in HIV infection
90. Nelfinavir: A review of its therapeutic efficacy in HIV infection
91. Rash as a side-effect of nelfinavir in children
92. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children
93. Spontaneous bleeding associated with the use of the protease inhibitor in a hemophiliac patient with human immunodeficiency virus infection
94. Early therapy with ritonavir (ritonavir), ZDV and 3TC in HIV-infected children 1-24 months of age
95. A phase III study of amprenavir in protease-inhibitor-naive and-experienced HIV-infected children and adolescents
96. A phase II study of amprenavir (amprenavir, 141W94, Agenerase) in antiretroviral-experienced children with HIV-infection
97. ABT-378/ritonavir in HIV-infected children
98. Kaletra (ABT-378/ritonavir) in HIV-infected children at 48 weeks
99. Kaletra (ABT-378/ritonavir) in HIV-infected children at 60 weeks
100. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection
101. A randomized trial of combination therapy with saquinavir soft gelatin capsules (saquinavir) in HIV-infected children
102. Crystalluria and urinary tract abnormalities associated with indinavir
103. Indinavir (indinavir) in combination with stavudine (d4T) and lamivudine (3TC) in HIV-infected children
104. Protease inhibitors in children with HIV infection
105. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
106. A pediatric case of HIV protease inhibitor-induced lipodystrophy
107. Abnormal body fat accumulations in HIV-infected children on antiretroviral therapy
108. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children
109. Abnormal body-fat distribution in HIV-infected children on antiretrovirals
110. Changes in regional fat distribution in HIV-infected children
111. Blood lipid levels and body composition in HIV-infected children treated with protease inhthitors
112. Hypercholesterolemia in children treated with protease inhibitors
113. Interactions among drugs for HIV and opportunistic infections
114. Drug interactions in patients infected with human immunodeficiency virus
115. Lopinavir
116. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
117. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
118. Steady-state pharmacokinetics of nelfinavir mesylate (nelfinavir; VIRACEPT) in HIV-infected children
119. Combination nucleoside analogs plus nelfinavir, nevirapine or ritonavir in stable antiretroviral therapy-experienced HIV-infected children
120. Twice daily nelfinavir in antiretroviral therapy experienced pediatric patients
121. Nelfinavir pharmacokinetics in combination with ritonavir in infants and children with advanced HIV disease
122. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1
123. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants
124. Virologic and CD4 response to treatment with nelfinavir in therapy experienced, protease inhibitor naive HIV-infected children: 48 Week follow-up
125. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
126. Pharmacokinetic interaction between DMP66 and nelfinavir mesylate in healthy volunteers
127. Four-drug rescue antiretroviral therapy including efavirenz and nelfinavir in highly treated children with HIV-disease
128. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection
129. A one year experience: T cell responses and viral replication in children with advanced human immunodeficiency virus type 1 disease treated with combination therapy including ritonavir
130. Loss of viral fitness associated with multiple gag and gag-pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
131. Lack of fitness of protease inhibitor-resistant HIV-1 in vivo
132. Response to ritonavir in severely immunocompromised, antiretroviral experienced children with perinatal HIV-1 infection
133. Virologic and immunologic responses in children with advanced HIV disease on a new HAART regimen (PACTG 366)
134. Effects of protease inhibitors combined with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type-1 infected children
135. Ritonavir promotes increased growth in HIV-infected children
136. Protease inhibitors significantly improve linear growth in HIV-infected children
137. Lack of improvement in growth in HIV-infected children on HAART
138. Combination therapy including ritonavir in children infected with human immunodeficiency
139. Amprenavir: A review of its clinical potential in patients with HIV infection
140. Pharmacokinetics of 141W94 after single dose administration in HIV-infected children
141. Pharmacokinetic drug-interaction between amprenavir and ritonavir in HIV-seronegative subjects after multiple, oral dosing
142. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations
143. Single dose pharmacokinetics of ABT-378 in combination with ritonavir
144. Assessment of pharmacokinetic interactions between Kaletra (lopinavir/ritonavir or ABT/378/r) and nevirapine in pediatric subjects
145. Saquinavir soft-gel capsule formulation, a review of its use in patients with HIV infection
146. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection
147. Population pharmacokinetics of indinavir, didanosine and stavudine in children
148. Indinavir pharmacokinetics and pharmacodynamics in children with human immunodeficiency virus infection
149. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy
150. The drug transporter p-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
151. Indinavir in cerebrospinal fluid of HIV-1-infected patients
152. Neurodevelopmental/neuroradiologic recovery of a child infected with HIV after treatment with combination antiretroviral therapy using the HIV-specific protease inhibitor ritonavir
153. Development of an indinavir syrup to treat HIV + children
154. Regeneration of CD4+45RA+ T lymphocytes in the presence of continued viral replication in HIV-infected children treated with 96 weeks of combination indinavir, 3TC and ZDV
155. Immune reconstitution and role of thymus during potent antiretroviral therapy in vertically HIV-infected children
156. Long term outcome of potent antiretroviral therapy in HIV-infected children
157. Pharmacokinetic interactions between ritonavir and indinavir in healthy volunteers
158. Single-dose pharmacokinetics of indinavir and the effect of food
159. Combining ritonavir and indinavir decreases indinavir associated nephrolithiasis
160. Pharmacokinetics of indinavir and low-dose ritonavir BID in children with HIV-infection